CliffBio
small molecule

ONGENTYS

OPICAPONE

Loss of exclusivityDecember 2032latest FDA-listed patent expiry
CompanyAmneal Pharmaceuticals →See this company's full patent-cliff portfolio

Drug detail

Brand nameONGENTYS
Active ingredientOPICAPONE
Strength50MG
Dosage formCAPSULE
RouteORAL
ModalitySmall molecule
FDA approvalApril 2020
Marketing statusRX

Listed patents

PatentExpiresType
9630955December 2032substance, product
12129247January 2032use U-4038
10583130March 2030use U-3869
10071085March 2030product
8524746July 2029use U-3869
8168793October 2027substance, product
9745290October 2027product
8907099May 2027substance
9550759July 2026use U-3872

More from Amneal Pharmaceuticals

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

ONGENTYS patent cliff — loss of exclusivity December 2032 | CliffBio